Tycho H. Heimbach, Ph.D.
Affiliations: | 2003 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Pharmacy, Pharmaceutical ChemistryGoogle:
"Tycho Heimbach"Mean distance: (not calculated yet)
Parents
Sign in to add mentorGordon L. Flynn | grad student | 2003 | University of Michigan | |
(Oral phosphate prodrugs: Absorption rate limit considerations.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Wu F, Mousa Y, Jereb R, et al. (2024) Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products. The Aaps Journal. 26: 19 |
Tsakalozou E, Mohamed MF, Polak S, et al. (2023) Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary. The Aaps Journal. 25: 96 |
Bauer A, Berben P, Chakravarthi SS, et al. (2023) Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group. Pharmaceutical Research |
Wu F, Mousa Y, Raines K, et al. (2022) Regulatory Utility of Physiologically Based Pharmacokinetic Modeling to Support Alternative Bioequivalence Approaches and Risk Assessment: A Workshop Summary Report. Cpt: Pharmacometrics & Systems Pharmacology |
Wu D, Sanghavi M, Kollipara S, et al. (2022) Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs. Pharmaceutical Research |
Lin W, Chen Y, Unadkat JD, et al. (2022) Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharmaceutical Research |
Aburub A, Chen Y, Chung J, et al. (2022) An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow. The Aaps Journal. 24: 49 |
Laisney M, Heimbach T, Mueller-Zsigmondy M, et al. (2022) Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption. Journal of Pharmaceutical Sciences. 111: 274-284 |
Heimbach T, Kesisoglou F, Novakovic J, et al. (2021) Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms Using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies. Journal of Pharmaceutical Sciences |
Jogiraju VK, Heimbach T, Toderika Y, et al. (2020) Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption. Drug Metabolism and Pharmacokinetics. 37: 100375 |